Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)

This document constitutes regulated information in the sense of the Royal Decree of 14 November 2007 and/or the Law of 2 August 2002. For the full press release, download the PDF document(s) above.